Mandate

Vinge advises Norra Affars on acquisition of Remium

July 06, 2016

Remium is a leading capital markets services provider in the small to medium sized enterprises segment offering e.g. corporate finance, equity research, asset management and corporate services. The acquisition is a strategic supplement to Norra Affärs’ business concept which primarily comprises lending to small to medium sized enterprises. The acquisition is expected to be completed early autumn 2016 after receipt of the relevant approvals from the Swedish Financial Supervisory Authority.

Vinge’s team consisted of among others partners Peter Sundgren (M&A) and Emma Stuart-Beck (financial regulatory) as well as associates Johan Mattsson and Marith Welin-Berger (M&A), Caroline Krassén and Henrik Schön (financial regulatory), Karin Isacson (employment & benefits) and Rebecka Weitzberg (intellectual property law).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026